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162Objectives: We analyzed the role of magnesium sulfate (MgSO4) supplementation during cardiopulmonary
bypass in pediatric patients undergoing cardiac surgery, assessing the incidence of hypomagnesemia and the in-
cidence of junctional ectopic tachycardia.
Methods:We performed a randomized, double-blind, controlled trial in 99 children. MgSO4 or placebo was ad-
ministered during the rewarming phase of cardiopulmonary bypass: group 1, placebo group (29 patients); group
2, 25 mg/kg of MgSO4 (30 patients); and group 3, 50 mg/kg of MgSO4 (40 patients).
Results: At the time of admission to the cardiac intensive care unit, groups receiving MgSO4 had significantly
greater levels of ionized magnesium (group 1, 0.51  0.07; group 2, 0.57  0.09; group 3, 0.59  0.09). Hypo-
magnesemia before bypass was common (75%–86.2%) and not significantly different among the groups. The
proportion of hypomagnesemia decreased significantly at admission to the cardiac intensive care unit in groups
receiving MgSO4 (group 1, 77.8%; group 2, 63%; group 3, 47.4%). Patients receiving placebo (group 1) had
a significantly greater occurrence of junctional ectopic tachycardia than groups receiving MgSO4 (group 1, n
¼ 5 [17.9%]; group 2, n ¼ 2 [6.7%]; group 3, n ¼ 0 [0%]). Age (<1 month), Aristotle score (>4), and history
of cardiac failure were associated with junctional ectopic tachycardia. None of the patients with those character-
istics in group 3 had junctional ectopic tachycardia. No association was found between study groups and the
Pediatric Risk of Mortality score or length of stay in the cardiac intensive care unit.
Conclusions: Supplementation with MgSO4 during cardiopulmonary bypass seems to reduce the incidence of
hypomagnesemia and junctional ectopic tachycardia at admission to the cardiac intensive care unit. This effect
seems to be dose related. (J Thorac Cardiovasc Surg 2010;139:162-9)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surgcongenital heart disease are especially vulnerable to rhythm
disturbances. In pediatric cardiac surgery, there is little
information regarding the incidence, risk factors, manage-
ment, and prophylaxis for early postoperative arrhythmias.
A recent report by Roos-Hesselink and Karamermer1 noted
an incidence between 15% and 17.7%. Postoperative junc-
tional ectopic tachycardia (JET) remains one of the most
common arrhythmias (8%–20%) after pediatric cardiac sur-
gery. JET is associated with hemodynamic instability, lon-
ger mechanical ventilation time, and longer stays in the
cardiac intensive care unit (CICU).2 Although the etiology
of JET is multifactorial, some studies have associated the
presence of JET with hypomagnesemia during cardiopulmo-
nary bypass (CPB).3
Magnesium is an important regulator of multiple cardio-
vascular processes, including myocardial conduction and
contractility, transmembrane calcium flux, potassium trans-
port, vascular smooth muscle tone, coronary reactivity, and
nitric oxide synthesis. One percent of total magnesium is dis-
tributed in the extracellular fluid, where 55% of it is in the
physiologic active form: ionized magnesium (iMg). Mea-
surement of iMg is currently available and its assessment
is reflective of the intracellular magnesium status.4,5ery c January 2010
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CICU ¼ cardiac intensive care unit
CPB ¼ cardiopulmonary bypass
iMg ¼ ionized magnesium
JET ¼ junctional ectopic tachycardia
MgSO4 ¼ magnesium sulfate
PRISM ¼ Pediatric Risk of MortalityP
MInasmuch as magnesium is an essential cofactor for the
maintenance of myocardial transmembrane potential, mag-
nesium deficiency decreases the threshold for arrhythmias.6
In adults having cardiac surgery, hypomagnesemia has been
associated with the presence of arrhythmias, especially post-
operative atrial fibrillation.7-10 Furthermore, in adults the ad-
ministration of magnesium sulfate (MgSO4) during cardiac
surgery reduces the occurrence of postoperative atrial fibril-
lation.11 In pediatric patients undergoing cardiac surgery
with CPB, hypomagnesemia is common (34%) and is asso-
ciated with longer CICU stay, higher Pediatric Risk of Mor-
tality (PRISM) score, and longer mechanical ventilation
time.12 Alhough magnesium supplementation during CPB
reduces the incidence of arrhythmias in adults, the benefits
of magnesium administration in pediatric cardiac patients
have not been demonstrated nor have dosage guidelines
been established.
The aim of this study was to determine the incidence of
hypomagnesemia in pediatric patients undergoing cardiac
surgery who require CPB and to evaluate the prophylactic
administration of magnesium on the occurrence of postoper-
ative arrhythmias. In addition, we study the influence of
magnesium supplementation on the length of CICU stay
and PRISM score.
METHODS
Study Population and Design
Between February 2005 and August 2006, we performed a randomized,
double-blind, placebo-controlled trial in pediatric cardiac surgery patients
requiring CPB. The study was approved by the Institutional Review
Board of the University of Pittsburgh, and written informed consent
was obtained from the parents of all the participants. Patients between
birth and 17 years of age scheduled for elective cardiac surgery were el-
igible. Those with any medical disorder that required magnesium supple-
mentation, such as malnutrition, sepsis, pancreatitis, or other conditions,
were excluded. Neonates whose mothers received MgSO4 before or dur-
ing the delivery, as well as patients who underwent emergency opera-
tions, were also excluded from the study. After informed written
consent had been obtained from a parent, each patient was randomly as-
signed to one of the following groups: group 1, receiving normal saline
(placebo), group 2, receiving 25 mg/kg of MgSO4, and group 3, receiving
50 mg/kg of MgSO4. Maximum total dose of MgSO4 did not exceed 2 g.
The study medication was prepared by the hospital pharmacy and was ad-
ministered in a 5-mL syringe. All subjects received a single bolus of ei-
ther placebo or drug into the CPB circuit at the initiation of the
rewarming period. MgSO4 (500 mg/mL; 4 mEq/mL) was produced by
SALF SpA (Cenate Sotto, Bergamo, Italy). Anesthesia was inducedThe Journal of Thoracic and Cawith sevoflurane and maintained with isoflurane, fentanyl, midazolam,
and rocuronium. The composition of the bypass circuit and perfusion pro-
tocols were performed according to established institutional practices. The
circuits were primed with a Plasma-Lyte solution (Baxter, Deerfield, Ill)
and reconstituted blood was used as necessary to achieve a patient hemat-
ocrit level greater than 25%. Heparin (350 mg/kg) was given to maintain
activated coagulation time greater than 300 seconds. A custom-made cold
blood cardioplegic solution was made according to previous protocols
with 3 mEq/L of MgSO4. All patients received methylprednisolone at
30 mg/kg in the prime of the CPB circuit. Conventional hemofiltration
was performed during CPB. Ultrafiltration was used at the end of CPB
in all patients less than 10 kg, removing 60 mL of fluid per every kilo-
gram of weight. A pH-stat acid–base management strategy was used
when deep hypothermic circulatory arrest was performed. Potassium chlo-
ride and calcium chloride were given to maintain normal serum concentra-
tions during surgery. At the end of the operation, all patients received
1mg/kg furosemide (maximumdose 20mg). Protaminewas given to reverse
heparin (1.3:1). No antiarrhythmics were administered during the operation
to any patient.At the end of the surgical procedure, all the patientswere trans-
ferred to the CICU. If clinically appropriate, patients were weaned from the
ventilator and extubated.Weaning from inotropic infusions in the CICUwas
guided by standard hemodynamic criteria. Postoperative JET was managed
by the CICU intensivist. The general approach to JET consisted of cooling
the patient to 34 Cand administering amiodarone (5mg/kg over 30minutes,
followed by an infusion of 15 mg/kg per day).
Study Measurements
The iMg level wasmeasured at 4 time points: (1) baseline (time 1), before
CPB; (2) approximately 10 minutes after initiation of the CPB (time 2); (3)
approximately 10 minutes after study solution administration during the re-
warming period of CPB (time 3); and (4) at the admission to the CICU (time
4). Arterial blood (1mL)was collected into a heparinized syringe (25USP of
dry heparin per milliliter) and iMg was immediately analyzed with the Ultra
C analyzer (Nova Biomedical, Waltham,Mass). All the measurements were
performed by the same operator and using the same machine. Quality con-
trols were performed each day of the study. The presence of hypomagnese-
mia was based on iMg reference levels adjusted for age.12 A 12-lead
electrocardiogram was performed on arrival in the CICU and an atrial elec-
trocardiogram, using the temporary epicardial atrial pacemaker electrode,
was used to verify the presence of JET. Detection of JET was made about
10 minutes after CICU admission. JET was defined as (1) a heart rate of
170 beats/min or more with a QRS complexmorphology similar to the base-
line normal sinus or atrial rhythm; (2) an atrioventricular dissociation with
a ventricular rate higher than or equal to the atrial rate; (3) a ventricular/atrial
association with a retrograde 1:1 or Wenckeback conduction. Preoperative
variables including demographics, previous medical history, and previous
electrocardiogram were collected. The classification of the surgery was as-
sessed by theAristotle level of complexity. (A complete list of the operations
is available online inTable E1.) Intraoperative variables includingCPB time,
crossclamp time, and cardiac circulatory arrest time were recorded. Heart
failure was defined by decreased ventricular function by echocardiography
and/or clinical evidence of congestive heart failure. The patient’s tempera-
ture, heart rate, central venous pressure, and mean blood pressure at the
time of iMg blood samples were also recorded. Postoperative ventricular
function assessed by echocardiography at CICU arrival, mechanical ventila-
tion time, PRISM III score, CICU length of stay, hospital length of stay, and
discharge status were also noted.
Statistical Analysis
The analysis was conducted on an intention-to-treat basis. Before the
analysis, data were checked to identify any data entry error or confirm the
outlier values. Data were stored electronically and were analyzed with
SPSS 15.0 software (www.spss.com), STATA 10 and R version 2.6.0
(http://www.r-project.org). We used the Kruskal–Wallis test for continuousrdiovascular Surgery c Volume 139, Number 1 163
TABLE 1. Baseline demographic and medical history characteristics by study group
Characteristics
Study group
Group 1: Placebo (n ¼ 29) Group 2: Mg ¼ 25 mg/kg (n ¼ 30) Group 3: Mg ¼ 50 mg/kg (n ¼ 40) P value*
Age (y)
Median (range) 3 (0–17) 1.54 (0–17) 1.37 (0–11) .34
Weight (kg)
Median (range) 14.6 (2.3–69) 8.1 (2.1–85) 7.0 (1.4–51) .20
BSA (m2/kg)
Median (range) 0.6 (0.18–1.7) 0.4 (0.17–1.98) 0.36 (0.14–1.4) .21
Gender (n/%)
Female 11/37.9 17/56.7 18/45.0 .34
Male 18/62.1 13/43.3 22/55.0
Congenital anomalies (n/%) 0/0 1/3.3 3/7.5 .38
Down syndrome (n/%) 2/6.9 6/20 3/7.5 .23
DiGeorge syndrome (n/%) 1/3.4 2/6.7 1/2.5 .82
Neurologic disease (n/%) 4/13.8 2/6.7 2/5.0 .48
Redo (n/%) 14/48.3 11/36.7 11/27.5 .2
Aristotle (n/%)
1 4/14.3 3/10.0 8/20.0 .24
2 6/21.4 11/36.7 14/35.0
3 14/50.0 14/46.7 10/25.0
4 4/14.3 2/6.7 8/20.0
Cardiac failure (n /%) 6/20.7 8/26.7 7/17.5 .64
Pulmonary hypertension (n/%) 2/6.9 6/20.0 4/10.0 .3
Asthma (n/%) 2/6.9 0/0 5/12.5 .11
Renal failure (n/%) 1/3.4 0/0 2/5 .63
Cardiogenic shock (n/%) 3/10.3 1/3.3 2/5 .58
Sinus rhythm 28/96.6 28/93.3 38/95 1.0
CPB time (min)
Median (range) 59 (32–184) 74.5 (30–235) 70.5 (15–255) .5
BSA, Body surface area; CPB, cardiopulmonary bypass. *(BSA¼O height 9 cm) weight (kg)/3600).
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Mvariables and c2 or Fisher’s exact tests for categorical variables to compare
demographics and medical history characteristics between study groups.
Fisher’s exact test was used to compare the proportion of hypomagnesemia
between the study groups. One-way analysis of variance was performed to
compare the average levels of iMg at each point in time by study groups,
using Bonferroni test for multiple comparisons. Fisher’s exact test was
used to compare the proportion of JET by study group and to determine
whether the proportion of JET after surgery was significantly different by
preoperative covariates. For those covariates that were found to be signifi-
cantly associated with the presence of JET in this univariate analysis, a strat-
ified analysis was performed to determine whether there was an association
between the presence of JET after surgery and study groups stratified by
these covariates. A log transformation was used because the distribution
of variable CICU length of stay was highly skewed. Linear regression
was used to compare the CICU length of stay among the 3 treatment
arms. Poisson regression was used in the analysis of the PRISM score.RESULTS
Study Population
Between February 2005 and August 2006, 99 patients
were included in the study. Twenty-nine patients were ran-
domly assigned to group 1 (placebo group), 30 patients to
group 2 (receiving 25 mg/kg of MgSO4), and 40 patients
to group 3 (receiving 50 mg/kg of MgSO4). The 3 groups
of patients were similar in regard to patient demographics
and preoperative and intraoperative variables (Table 1).164 The Journal of Thoracic and Cardiovascular SurgAnalysis of iMg Level and Incidence of
Hypomagnesemia
The average of iMg level at each time point was compared
among the study groups. The levels of iMg at time 1 and
time 2 were not significantly different among the 3 groups
(P¼ .9 and .5, respectively). In the 3 study groups, iMg level
significantly increased at time 3 (10 minutes after the admin-
istration of the study) and decreased again at time 4 (CICU
admission) (Figure 1). At time 3, the average of iMg level in
group 3 (50 mg/kg of MgSO4) was significantly greater than
the levels in groups 1 and 2 (group 1, 0.56  0.16; group 2,
0.73  0.21; group 3, 0.93  0.24; P ¼ .0001). Moreover,
both groups 2 and 3 had significantly greater levels of iMg
at time 4 than did the placebo (group 1, 0.51  0.07; group
2, 0.57  0.09; group 3, 0.59  0.09; P ¼ .0001) (Table 2).
Hypomagnesemia was common, and no significant differ-
ence was found among the study groups before CPB (group
1, 75%; group 2, 86.2%; group 3,83.3%; P ¼ .6) (data
available online in Table E2). The proportion of hypomag-
nesemia was not significantly different at time 2 among
the study groups, just before the solution administration
(group 1, 92.6%; group 2, 86.7%; group 3, 88.9%; P ¼
.8). There were significant differences in the proportion of
hypomagnesemia among the 3 groups at time 3 (group 1,ery c January 2010
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FIGURE 1. Average ionized magnesium (iMg) level by study group over
time. Time 1, Baseline; time 2, 10minutes after initiation of CPB; time 3,
10minutes after study solution; time 4, At the CICU admission. *P value
< .05.
TABLE 2. Ionizedmagnesium level at each time point by study groups
Time
points
Ionized magnesium level by study group (mean ± SD)
P
value*
Group 1:
Placebo
Group 2:
Mg ¼ 25 mg/kg
Group 3:
Mg ¼ 50 mg/kg
T1 n ¼ 28 n ¼ 29 n ¼ 36 .9
0.52  0.07 0.52  0.10 0.53  0.06
T2 n ¼ 27 n ¼ 30 n ¼ 36 .5
0.48  0.07 0.46  0.08 0.48  0.08
T3 n ¼ 28 n ¼ 29y n ¼ 38y,z .0001
0.56  0.16 0.73  0.21 0.93  0.24
T4 n ¼ 27 n ¼ 27y n ¼ 38y .0001
0.51  0.07 0.57  0.09 0.59  0.09
T1,Before surgery; T2, during surgery and before trial intervention; T3, during surgery
and after trial intervention; T4, after surgery at cardiac intensive care unit; SD, standard
deviation. *One-way analysis of variance: yDiffered significantly from placebo;
zdiffered significantly from mg ¼ 25 mg/kg.
Manrique et al Perioperative Management60.7%; group 2, 27.6%; group 3, 13.2%; P< .01). Both
groups 1 and 2 reported significantly greater proportion of
hypomagnesemia than group 3 at time 3. The same pattern
could be noticed at time 4; however, the P value was margin-
ally significant (group 1, 77.8%; group 2, 63.0%; group 3,
47.4%; P ¼ .05) (data available online in Table E2).P
MAnalysis of JET
Univariate analysis. The total incidence of JET was 7.0%
for the 99 patients. The unadjusted analysis showed that
there were significant differences in the proportion of JET
among the 3 study groups. Group 1 (placebo group) patients
had a significantly greater proportion of JET than group 2
and group 3 patients (group 1, n ¼ 5 [17.9%]; group 2, n
¼ 2 [6.7%]; group 3, n ¼ 0 [0%]; P ¼ .009). Both age
and Aristotle score are also marginally associated with the
occurrence of JET. Patients who were 1 month of age or
less were more likely to have JET after surgery than were
the other age categories (1 month, 21.4%; 1 month to 1
year, 7.1%;>1 year, 3.6%; P ¼ .06). Moreover, patients
with an Aristotle score of 4 or more were more likely to
have JET than were those with a score of less than 4
(21.3% vs 4.8%; P¼ .06). History of cardiac failure before
the operation was found to be significantly associated with
the occurrence of JET after the operation: 19.1% of the pa-
tients who had cardiac failure before surgery had JET com-
pared with 3.9% of those who did not have a history of
cardiac failure (P ¼ .03). CPB time was marginally associ-
ated with the development of JET (P ¼ .05). In addition, 5
(71%) of 7 patients with JET were hypomagnesemic at
the CICU admission.
Stratified analysis. We analyzed the association between
the occurrence of JET and study groups stratified by Aristo-The Journal of Thoracic and Catle score and age group (Table 3). Other potential con-
founders, including potassium, calcium, glucose, base
excess, and pH levels at each time point were similarly dis-
tributed among the 3 study groups.Analysis of CICU Length of Stay
Both treatment groups tended to spend a longer time in the
CICU than the placebo group; however, this difference was
not statistically significant (group 1, 1.08 0.75 days; group
2, 1.30 1.13 days; group 3, 1.23 0.91 days; P¼ .7). We
analyzed the main covariates that were significantly or mar-
ginally significantly associated with CICU length of stay in
a univariate linear regression. Positive significant associa-
tions were reported between Aristotle score, the history of
cardiac failure, CPB time, and CICU length of stay. After ad-
justing for CPB time, cardiac failure, and Aristotle score, the
CICU length of stay in each of the 2 treatment groups was
not significantly different from that in the placebo group
(data available online in Table E3). CPB time, Aristotle
score of 4 or more, and a history of cardiac failure were
found to be independent predictors of the CICU length of
stay from the multivariate model.Analysis of PRISM Score
Aristotle scores and CPB times of more than 60 min-
utes were found to be significantly associated with
PRISM score (P ¼ .02 and .01, respectively). Although
both treatment groups had higher PRISM scores, the
scores were not statistically significant compared with
placebo (P ¼ .5). Even after adjusting the effect of
asthma, Aristotle score, CPB time (dichotomized into
 60 minutes or> 60 minutes), and using a multivariate
Poisson regression, the PRISM score did not significantly
differ among the treatment groups. History of asthma and
CPB time of more than 60 minutes were found to be in-
dependently associated with a greater PRISM score (data
available online in Table E4).rdiovascular Surgery c Volume 139, Number 1 165
TABLE 3. Proportion distribution of JETarrhythmia by study groups
stratified by significant and marginal significant covariates
Study group
P
value*
Group 1:
Placebo
Group 2:
Mg ¼ 25 mg/kg
Group 3:
Mg ¼ 50 mg/kg
Age
 1 mo (n) 5y 3 6 .03*
JET yes (n) (3) 60% (0) 0% (0) 0%
1 mo to 1 y (n) 4 11 13 .1
JET yes (n)% (1) 25% (1) 9.1% (0) 0%
>1 y (n) 19 16 21 .5
JET yes (n)% (1) 5.3% (1) 6.3% (0) 0%
Aristotle score
<4 (n) 23 28 32 .06
JET yes (n)% (3) 13.0% (1) 3.6% (0) 0%
4 (n) 4 2 8 .07
JET yes (n)% (2) 50% (1) 50% (0) 0%
Cardiac failure
Yes (n) 6 8 7 .06
JET yes (n)% (2) 33.3% (2) 25.0% (0) 0%
No (n) 22 22 33 .04*
JET yes (n)% (3) 13.6% (0) 0% (0) 0%
CPB time (min)
 60 (n) 15 10 17 .6
JET yes (n)% (1) 6.7% (0) 0% (0) 0%
>60 (n) 13 20 23 .01
JET yes (n) (4) 30.8% (2)10% (0) 0%
JET, Junctional ectopic tachycardia; CPB, cardiopulmonary bypass. *Fisher’s exact
test; yn is the total of column variable.
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MAdverse Effects
No episodes of severe bradycardia or hypotension were
reported. The incidences of renal failure or cardiac dysfunc-
tion were similar in the 3 study groups.DISCUSSION
In this study, we found that in children undergoing cardiac
surgery with CPB, the administration of a single dose of
MgSO4 during CPB reduces the incidence of hypomagnese-
mia by 30% and also decreases the incidence of postopera-
tive JET at the time of CICU admission. In addition, this
effect of magnesium seems to be dose related. None of the
patients who received 50 mg/kg of MgSO4 had JET as de-
tected on arrival in the CICU, whereas the incidence of
JET was 6.7% in patients who received 25 mg/kg of
MgSO4 and 17.9% in patients who received placebo. The
overall incidence of JET in our study population was
6.9%, comparable with the same incidence described in pre-
vious reports.13,14Level of iMg and Hypomagnesemia
Our data suggest that supplementation of magnesium dur-
ing CPB reverses hypomagnesemia and reduces the fre-
quency of JET as detected on arrival in the CICU.166 The Journal of Thoracic and Cardiovascular SurgThis finding supports the notion that iMg levels during
CPB are clinically relevant and hypomagnesemia should
be aggressively treated to potentially prevent JET in the im-
mediate postoperative period. Although we do not know the
specific mechanism by which the appropriate magnesium
level during CPB prevents JET, we speculate that magne-
sium stabilizes the myocyte ionic channels leading to myo-
cardial protection and electrical equilibrium. The critical
iMg level that protects the myocardium during CPB is un-
known, but it may vary among different pathologic condi-
tions, surgical strategies, and degrees of injury.
As in previous studies,12 our data at the time of the CICU
admission showed that the frequency of hypomagnesemia
was marginally higher between placebo and magnesium
groups. We speculate that this difference may be clinically
insignificant. This little difference may be explained by mul-
tiple factors that occur after CPB and influence whole blood
magnesium levels, such as ultrafiltration, intravenous fluids,
blood transfusions, and drugs.14-16
Preoperative factors may include the fact that many of
those cardiac patients are receiving medications that increase
the renal loses of magnesium, such as diuretics and digitalis.
Moreover, during the operation, patients are exposed to he-
modilution, blood loss, blood transfusions, and an increase
of catecholamines that cause chelation of magnesium. All
of these are factors that contribute to the decrease in plasma
magnesium levels. In addition, during surgery, continuous
hemofiltration, modified ultrafiltration, and administration
of large doses of calcium and diuretics can all cause deple-
tion of magnesium. Other factors causing hypomagnesemia
include the intracellular elimination shifts induced by the ex-
tracorporeal circulation and the decrease in body tempera-
ture during surgery.5,15-20 As expected, in both groups of
patients receiving magnesium, the levels of iMg increased
after the administration of the MgSO4. This increase was
higher in the group receiving 50 mg/kg of MgSO4 where
the highest levels of iMg were close to the upper level of
normal for age. In the placebo group, there was also a slight
elevation in the levels of iMg at time 3. This effect may be
related to the hemoconcentration during the rewarming pe-
riod of CPB and to the administration of the cardioplegic so-
lution containing magnesium. However, in our opinion, the
effect of the cardioplegic solution should not be significant
because the solution used is a custom prepared solution con-
taining a low concentration of magnesium. We observed
a progressive decrease in the iMg level in the 3 groups dur-
ing CPB after time 3 (approximately 10 minutes after the
administration of the study medication) and at CICU arrival.
This reduction may be explained by several factors occur-
ring during the operation, such as the administration of di-
uretics, transfusion of blood products, increase in
exogenous catecholamines, and the modified ultrafiltration
performed at the end of CPB. Although iMg levels are sim-
ilar between both magnesium groups at CICU arrival, theseery c January 2010
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Mlevels are significantly higher than those of the placebo
group, indicating a beneficial effect of the administration
of MgSO4 during CPB.
JET and Antiarrhythmic Effect of Magnesium
The presence of early postoperative arrhythmias is a pre-
dictor for late complications such as ventricular dysfunction,
late arrhythmias, and late mortality.2,14,21,22 Thus, the pre-
vention of these arrhythmias will improve the postoperative
course and outcomes. In adults after cardiac surgery, one of
the most common supraventricular arrhythmias is atrial fi-
brillation. Several studies have demonstrated the role of hy-
pomagnesemia in the development of postoperative atrial
fibrillation and the prophylactic effect of the supplementa-
tion with MgSO4 during or after surgery.
23 In the early post-
operative period after pediatric cardiac surgery, one of the
most common arrhythmias is JET. The occurrence of post-
operative JET has been associated with longer CICU stay
and longer mechanical ventilation time. Etiologic factors
related to the development of JET are not completely
clear.2,13,14
Magnesium is the second most important intracellular di-
valent cation and is an obligatory cofactor for many of the
enzyme systems involved in energy metabolism. Magne-
sium also acts as a natural calcium antagonist, regulating cal-
cium access into the cell and contributing to the generation
and regulation of ion channel transport processes in the my-
ocytes. The antiarrhythmic effects of magnesium in poly-
morphic ventricular tachyarrhythmia have been attributed
to a decrease in inward calcium current via L-type calcium
channels and to the stabilization of the membrane potential
by facilitation of potassium entry into the cells, from the en-
hancement of sodium–potassium adenosine triphosphatase
as a cofactor. Therefore, magnesium increases the negative
membrane resting potential reducing myocardial excitabil-
ity. Magnesium infusion during supraventricular tachycar-
dia has been shown to prolong tachycardia cycle length by
delaying the atrioventricular nodal conduction. It increases
the relative refractory period and decreases the vulnerable
period, reducing the risk for re-entry.4,24-26 Myocardial dys-
function after surgery is a risk factor for the development of
JET according to previous studies.7,13,14 Newborns and chil-
dren are more susceptible to arrhythmias and myocardial
dysfunction after cardiac surgery. In the immature myocar-
dium, most of the calcium required for myocardial contrac-
tion is provided by the sarcoplasmic reticulum, which is still
underdeveloped and has a reduced storage capacity for cal-
cium. This immature heart is more sensitive to extracellular
calcium levels than the mature myocardium. JET is gener-
ated by an enhanced automaticity or triggered activity on
an ectopic focus within the atrioventricular node or the prox-
imal His bundle.25 Conditions that increase the likelihood of
enhanced abnormal automaticity are very common during
CPB and include ischemia, electrolyte imbalances, catechol-The Journal of Thoracic and Caamine excess, and certain drug toxicities.27 The prophylactic
effect of magnesium is related to its capacity to decrease the
catecholamine release from the adrenal medulla and adrener-
gic nerve endings.26 In addition, animal studies have shown
that MgSO4 attenuates the degree of myocardial necrosis
and plays a cardioprotective role in ischemia–reperfusion in-
jury. The beneficial effect of the administration of MgSO4
during the reperfusion period of CPB could result from the
maintenance of the stabilization of the membrane and the re-
duction of the vulnerability to automatic and re-entry mech-
anism.11 Hypomagnesemia has also been associated with the
presence of JET in previous studies. Supplementation with
MgSO4 during CPB reduces incidence of all arrhythmias
in adults and children. Dittrich and associates,28 in their ran-
domized clinical trial in 131 patients, demonstrated the asso-
ciation between the supplementation with magnesium and
a decrease in the overall incidence of postoperative arrhyth-
mias in children and adults after surgery for congenital heart
disease. They used an infusion of magnesium chloride after
CPB that can cause less toxicity thanMgSO4. They analyzed
serum and iMg levels and the presence of arrhythmias at the
CICU. There are some important limitations of this study
that should be highlighted, such as that the assignment to
study groups was not blinded in the moment of assessment
of the occurrence of arrhythmias. They also used a cardiople-
gic solution with a high content of magnesium, which may
explain the lower incidence of hypomagnesemia at CICU
admission, compared with our findings. Dorman and associ-
ates3 also developed a double-blind clinical trial in 28 pedi-
atric patients after surgery for congenital heart disease. On
this occasion, the group receiving 30 mg/kg of MgSO4 ad-
ministered in a single bolus at the end of CPB was compared
with a placebo group. The fact that they analyzed the serum
levels of total magnesium and not the iMg levels could ex-
plain the lower incidence of hypomagnesemia is this study.
Previous studies have demonstrated that patients might have
ionized hypomagnesemia with normal serum levels of total
magnesium.12,15,20 In this study, physicians were unblinded
if patients required antiarrhythmic therapy. The study was
designed for 100 patients and was stopped prematurely after
finding 4 cases of JET, which were all in the placebo group.
Any of those studies were developed specifically for the de-
tection of incidence of JET; however, these 2 well-designed
studies consistently demonstrated a decrease in the inci-
dence of postoperative arrhythmias with the administration
of magnesium. The supplementation of magnesium was per-
formed in both cases after CPB. As previously described,
hypomagnesemia is a persistent finding all through CPB
and the correction of it at that point can be critical to reach
an adequate myocardial protection and consequently
achieve a reduction of postoperative arrhythmias. We con-
sider that the administration of a single dose of MgSO4 dur-
ing CPB is a safer practice and can have a protective effect at
the moment of heart reperfusion.rdiovascular Surgery c Volume 139, Number 1 167
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factors associated with the presence of JET, including
younger age at the time of surgery, longer CPB duration,
higher surgical complexity, use of high inotropic support,
underlying congenital heart disease, and extension of the
myocardial injury.2 In our stratified analysis, we found
younger age (<1 month), higher complexity of surgery
(Aristotle score  4), and previous history of cardiac fail-
ure as significant or marginally significant covariates asso-
ciated with the development of JET, corroborating those
previous findings. However, we did not find any significant
difference in patients with longer CPB. We also did not
find any significant difference in the level of other electro-
lytes, the intraoperative use of inotropic support, and time
of rewarming.
CICU Length of Stay and PRISM Score
In a previous study, patients older than 1 month of age
with hypomagnesemia during CPB had a longer period of
mechanical ventilation, longer CICU stay, and a tendency
for a higher PRISM III score.12 We did not have the same
finding in our study; however, this can be a consequence
of the sample size. We found as independent significant pre-
dictors for the PRISM score asthma and longer CPB,
whereas history of cardiac failure, complexity of surgery,
and CPB time were found as independent predictors for lon-
ger CICU stay.
Limitations of the Study
Even though baseline characteristics and surgical com-
plexity were equal in our study groups, this population
does not represent all the pediatric cardiac surgical patients
who may be at risk for postoperative JET. For example, pa-
tients requiring emergency surgery and patients who were
critically ill (preoperatively) were not included in the study.
In addition, our study was not designed to evaluate the inci-
dence of JET after CICU admission. Thus the incidence of
JET and/or other arrhythmias over a prolonged postopera-
tive period was not evaluated. Another limitation of the
study is the lack of available tools to measure intracellular
activity of the magnesium. Intracellular magnesium may
be more of an indicator of hypomagnesemia and arrhyth-
mias. The low incidence of JET limits the number of patients
for analysis. A study with a large number of patients will be
needed to validate our results.
CONCLUSIONS
This study suggests that MgSO4 supplementation during
CPB reduces the incidence of hypomagnesemia and de-
creases the incidence of JET at the time of CICU admission.
In addition, this effect seems to be dose related.
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TABLE E1. Surgical procedures and frequency of JET
Group 1: Placebo JET Group 2: 25 mg/kg JET Group 3: 50 mg/kg JET Total JET
Surgery Y ¼ 1 N ¼ 0 Y ¼ 1 N ¼ 0 Y ¼ 1 N ¼ 0 Y ¼ 1, N ¼ 0
1 0 1 0 1 0
Fontan 1 8 0 2 0 2 1
Sano 1 1 0 1 0 0 1
TOF repair 1 2 0 6 0 4 1
ASD closure 0 2 0 1 0 4 0
Mitral valve repair 0 0 0 1 0 1 0
VSD closure 0 2 1 4 0 5 1
Ross procedure 0 0 0 0 0 1 0
Lung transplant 0 0 1 0 0 0 1
Septostomy 0 1 0 0 0 0 0
RV-PA conduit 1 0 0 1 0 1 1
RVOT repair 0 0 0 2 0 1 0
AVC repair 0 1 0 3 0 5 0
Aortic arch and VSD repair 1 0 0 1 0 1 1
PAPVC repair 0 0 0 1 0 2 0
Subaortic membrane resection 0 2 0 2 0 4 0
Subaortic stenosis repair 0 0 0 1 0 0 0
VSD and ASD closure 0 1 0 0 0 1 0
Aortic aneurysm repair 0 0 0 0 0 1 0
TOF,VSD-MAPCA repair 0 0 0 1 0 0 0
Arterial switch 0 0 0 0 0 4 0
Glenn 0 1 0 0 0 0 0
Truncus repair 0 0 0 0 0 1 0
Aortic translocation 0 0 0 0 0 1 0
Aortic valve repair 0 0 0 1 0 0 0
TAPVR 0 0 0 0 0 1 0
Mustard modified 0 1 0 0 0 0 0
JET, Junctional ectopic tachycardia; TOF, tetralogy of Fallot; ASD, atrial septal defect; VSD, ventricular septal defect; RV-PA, right ventricular–pulmonary artery; RVOT, right
ventricular outflow tract; AVC, atrioventricular canal; PAPVC, partial anomalous pulmonary venous connection; MAPCA, major aortopulmonary collateral artery; TAPVR, total
anomalous pulmonary venous return.
TABLE E2. Hypomagnesemia* at each time point by study groups
Time
pointsy
Proportion of hypomagnesemia (%)
P
valuez
Group 1:
Placebo
Group 2:
Mg ¼ 25 mg/kg
Group 3:
Mg ¼ 50 mg/kg
T1 n ¼ 28 n ¼ 29 n ¼ 36 .6
75% 86.2% 83.3%
T2 n ¼ 27 n ¼ 30 n ¼ 36 .8
92.6% 86.7% 88.9%
T3 n ¼ 28 n ¼ 29 n ¼ 38 <.000001*
60.7% 27.6% 13.2%
T4 n ¼ 27 n ¼ 27 n ¼ 38 .05
77.8% 63.0% 47.4%
*Presence of hypomagnesemia was based on ionized magnesium level adjusted for age
as follows: for age1 month: 0.46 mmol/L (0.43–0.49 mmol/L), for age 1 month to 1
year: 0.72 mmol/L (0.67–0.74 mmol/L), for age 1 year to 19 years: 0.63 mmol/L
(0.59–0.67), for age20 years: 0.53 mmol/L (0.51–0.54). yT1, Before surgery; T2,
during surgery and before trial intervention; T3, during surgery and after trial interven-
tion; T4, after surgery at cardiac intensive care unit. zFisher’s exact test.
TABLE E3. Multivariate linear regression to test of length of stay in
cardiac intensive care unit* was significantly associated with study
group after adjusting for study covariates
Regression coefficient 95% CI
P
value*
P value <.0001
R2 0.38
Covariates
Group 2y 0.19 (0.22, 0.60) .4
Group 3 0.07 (0.30, 0.45) .7
CPB time* 0.50 (0.13, 0.87) .008
Weight 0.01 (0.02, 0.001) .06
Aristotle score4 0.60 (0.07, 1.12) .03
Cardiac failure 0.52 (0.11, 0.93) .01
CI, Cardiac index; CPB, cardiopulmonary bypass. *Log transformation; yplacebo and
Aristotle<4 were reference groups.
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TABLE E4. Multivariate Poisson regression to test whether PRISM
score was significantly associated with study group after adjusting
for study covariates
Covariates IRR 95% CI P value*
Pseudo R2 .043
Covariates
Group 2y 1.37 (0.98, 1.89) .06
Group 3 1.12 (0.82, 1.52) .5
Asthma 2.05 (1.33, 3.17) .001
Aristotle score  4 1.16 (0.80, 1.68) .4
CPB time>60 minz 1.18 (1.03, 1.36) .015
PRISM, Pediatric Risk of Mortality; CI, confidence interval; CPB, cardiopulmonary
bypass. *Log transformation; yPlacebo and Aristotle<4 were reference groups.
zCPB time  60 minutes was the reference group.
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